ECSP088712A - Compuestos de n-formil-hidroxilamina - Google Patents

Compuestos de n-formil-hidroxilamina

Info

Publication number
ECSP088712A
ECSP088712A EC2008008712A ECSP088712A ECSP088712A EC SP088712 A ECSP088712 A EC SP088712A EC 2008008712 A EC2008008712 A EC 2008008712A EC SP088712 A ECSP088712 A EC SP088712A EC SP088712 A ECSP088712 A EC SP088712A
Authority
EC
Ecuador
Prior art keywords
compounds
formil
hydroxylamine compounds
disclosed
formyl hydroxylamine
Prior art date
Application number
EC2008008712A
Other languages
English (en)
Inventor
Kwangho Lee
Jennifer Leeds
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088712A publication Critical patent/ECSP088712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se dan a conocer novedosos compuestos de N-formil-hidroxilamina y sus derivados. Estos compuestos de N-formil-hidroxilamina inhiben la peptidil-desformilasa (PDF), una enzima presente en los procariotes. Los compuestos son útiles como antimicrobianos y antibióticos. Los compuestos de la invención exhiben una inhibición selectiva de la peptidil-desformilasa contra otras metaloproteinasas, tales como MMPs. También se dan a conocer métodos de preparación y uso de los compuestos.
EC2008008712A 2006-03-03 2008-09-02 Compuestos de n-formil-hidroxilamina ECSP088712A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77937706P 2006-03-03 2006-03-03

Publications (1)

Publication Number Publication Date
ECSP088712A true ECSP088712A (es) 2008-10-31

Family

ID=38510154

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008712A ECSP088712A (es) 2006-03-03 2008-09-02 Compuestos de n-formil-hidroxilamina

Country Status (19)

Country Link
US (1) US20090062537A1 (es)
EP (1) EP1994027A2 (es)
JP (1) JP2009529008A (es)
KR (1) KR20080095895A (es)
CN (1) CN101395148A (es)
AU (1) AU2007226715A1 (es)
BR (1) BRPI0708524A2 (es)
CA (1) CA2643267A1 (es)
CR (1) CR10251A (es)
EC (1) ECSP088712A (es)
GT (1) GT200800170A (es)
IL (1) IL193524A0 (es)
MA (1) MA30285B1 (es)
MX (1) MX2008011128A (es)
NO (1) NO20084069L (es)
RU (1) RU2008139192A (es)
TN (1) TNSN08344A1 (es)
WO (1) WO2007106670A2 (es)
ZA (1) ZA200807054B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101584694B (zh) * 2009-06-15 2011-01-12 华东师范大学 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法
CN101869563B (zh) * 2010-07-02 2011-11-16 华东师范大学 含4-亚甲基吡咯烷的肽脱甲酰基酶抑制剂
AR085698A1 (es) * 2011-03-09 2013-10-23 Glaxosmithkline Llc Inhibidores de la peptido desformilasa
CN103159660B (zh) * 2011-12-08 2016-07-06 天津市国际生物医药联合研究院 (2r)-1-(2-甲基-3-(甲氧基(甲基)氨基)-丙酰基)吡咯烷-2-羧酸及其应用
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
EP3608317A1 (en) 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
RU2014137052A (ru) 2012-02-24 2016-04-10 Ф.Хоффманн-Ля Рош Аг Противовирусные соединения
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
AU2015213900B2 (en) * 2014-02-06 2018-12-13 Nxera Pharma Uk Limited Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN108601764A (zh) 2015-03-18 2018-09-28 阿尔维纳斯股份有限公司 用于靶蛋白的增强降解的化合物和方法
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
AU2016349781A1 (en) 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
US20180072711A1 (en) 2016-09-15 2018-03-15 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
PL3660004T3 (pl) 2016-10-11 2023-10-02 Arvinas Operations, Inc. Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
CN110234646A (zh) 2016-11-01 2019-09-13 阿尔维纳斯股份有限公司 靶向PROTAC的Tau蛋白及相关使用方法
US10647698B2 (en) 2016-12-01 2020-05-12 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
EP3558994A4 (en) 2016-12-23 2021-05-12 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
AU2018211975B2 (en) 2017-01-26 2022-05-26 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
KR20240095318A (ko) 2018-04-04 2024-06-25 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
JP7548992B2 (ja) 2019-07-17 2024-09-10 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化化合物および関連する使用方法
TW202136240A (zh) 2019-12-19 2021-10-01 美商亞文納營運公司 用於靶向降解雄激素受體之化合物及方法
CA3181782A1 (en) 2020-05-09 2021-11-18 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
CN117279910A (zh) 2021-04-16 2023-12-22 阿尔维纳斯运营股份有限公司 Bcl6蛋白水解的调节剂和其相关使用方法
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036053A1 (es) * 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
EP1599440A2 (en) * 2003-02-21 2005-11-30 Novartis AG Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds

Also Published As

Publication number Publication date
CN101395148A (zh) 2009-03-25
MA30285B1 (fr) 2009-03-02
IL193524A0 (en) 2009-08-03
NO20084069L (no) 2008-12-03
CR10251A (es) 2008-10-27
TNSN08344A1 (en) 2009-12-29
JP2009529008A (ja) 2009-08-13
WO2007106670A3 (en) 2008-01-24
MX2008011128A (es) 2008-09-08
RU2008139192A (ru) 2010-04-10
WO2007106670A2 (en) 2007-09-20
CA2643267A1 (en) 2007-09-20
BRPI0708524A2 (pt) 2011-05-31
ZA200807054B (en) 2009-10-28
EP1994027A2 (en) 2008-11-26
US20090062537A1 (en) 2009-03-05
KR20080095895A (ko) 2008-10-29
AU2007226715A1 (en) 2007-09-20
GT200800170A (es) 2008-10-29

Similar Documents

Publication Publication Date Title
ECSP088712A (es) Compuestos de n-formil-hidroxilamina
AR056360A1 (es) Compuestos de n- formil- hidroxilamina
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20091395L (no) Nye tiofenderivater
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
GT200600117A (es) Nuevos compuestos farmaceuticos
WO2007077186A8 (en) Pdf inhibitors
BRPI0511133A (pt) uso de galacto-oligossacarìdeos e polifrutose
BR112013014119A8 (pt) Novos moduladores e métodos de uso
UY30748A1 (es) Compuesto0s novedosos
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
GT200900186A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
CO6351784A2 (es) Formas cristalinas de dimetoxi-docetaxel y sus procedimeintos de preparacion
IN2012DN02580A (es)
BRPI0717266A2 (pt) Derivados de oxindol
RS53868B1 (en) ATP-BINDING CASSETTE TRANSPORT MODULATORS
UA94412C2 (en) Glutamate aggrecanase inhibitors
NO20054790D0 (no) Anvendelse av B7-113 som et immunoregulatorisk middel
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
BRPI0508894A (pt) meios para administração transdérmica de nicotina e uso
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CL2011000087A1 (es) Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
CR11441A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
EA201000070A1 (ru) Модуляторы калликреина 7